Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350415 · ClinicalTrials.gov registry record · Phase 3
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 772
- Enrollment target
NCT00350415: Completed Phase 3 study, sponsored by Warner Chilcott.
NCT00350415 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 772 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350415, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 772 participants
- Enrollment target
Study Summary
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
Interventions
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 772 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00350415 record still lists
NCT00350415 is an interventional study that assigns participants to a tested intervention. The registered 772 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Mesalamine is the first listed.
NCT00350415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00350415 about?
NCT00350415 is a clinical study titled "A Double Blind Study for the Treatment of Acute Ulcerative Colitis". A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
What is the current status of trial NCT00350415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 772 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00350415?
The interventions under investigation include: Mesalamine (DRUG).
Who is sponsoring clinical trial NCT00350415?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00350415's enrollment target sits among peer trials
772 440th of 2000 higher than 1,561 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia